Everolimus for the treatment of advanced, nonfunctional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

BACKGROUND: Effective systemic therapies for patients with progressive neuroendocrine tumours of lung or gastrointestinal tract are limited. We aimed to assess the efficacy and safety of everolimus in this patient population. METHODS: In RADIANT-4, a randomised, double-blind, placebo-controlled, pha...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Lancet
Glavni autori: Yao, James C, Fazio, Nicola, Singh, Simron, Buzzoni, Roberto, Carnaghi, Carlo, Wolin, Edward, Tomasek, Jiri, Raderer, Markus, Lahner, Harald, Voi, Maurizio, Pacaud, Lida Bubuteishvili, Rouyrre, Nicolas, Sachs, Carolin, Valle, Juan W, Fave, Gianfranco Delle, Van Cutsem, Eric, Tesselaar, Margot, Shimada, Yasuhiro, Oh, Do-Youn, Strosberg, Jonathan, Kulke, Matthew H, Pavel, Marianne E
Format: Artigo
Jezik:Inglês
Izdano: 2015
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6063317/
https://ncbi.nlm.nih.gov/pubmed/26703889
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(15)00817-X
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items